Cornerstone Investment Partners LLC Purchases Shares of 6,834 Roche Holdings AG Basel ADR (RHHBY)

Share on StockTwits

Cornerstone Investment Partners LLC purchased a new position in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 6,834 shares of the company’s stock, valued at approximately $206,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Fisher Asset Management LLC lifted its holdings in shares of Roche Holdings AG Basel by 2.9% in the 2nd quarter. Fisher Asset Management LLC now owns 17,269,681 shares of the company’s stock worth $479,484,000 after acquiring an additional 489,609 shares during the last quarter. Boston Common Asset Management LLC lifted its holdings in shares of Roche Holdings AG Basel by 28.7% in the 2nd quarter. Boston Common Asset Management LLC now owns 497,686 shares of the company’s stock worth $13,818,000 after acquiring an additional 110,858 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in shares of Roche Holdings AG Basel by 2.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 320,110 shares of the company’s stock worth $8,888,000 after acquiring an additional 9,136 shares during the last quarter. Ferguson Wellman Capital Management Inc. lifted its holdings in shares of Roche Holdings AG Basel by 3.0% in the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 313,772 shares of the company’s stock worth $8,670,000 after acquiring an additional 9,025 shares during the last quarter. Finally, Pillar Pacific Capital Management LLC lifted its holdings in shares of Roche Holdings AG Basel by 3.8% in the 2nd quarter. Pillar Pacific Capital Management LLC now owns 154,118 shares of the company’s stock worth $4,279,000 after acquiring an additional 5,635 shares during the last quarter. 0.57% of the stock is owned by institutional investors and hedge funds.

OTCMKTS RHHBY traded up $0.73 during trading on Friday, hitting $30.57. The company had a trading volume of 914,215 shares, compared to its average volume of 903,955. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $203.10 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 1.88 and a beta of 0.62. Roche Holdings AG Basel ADR has a one year low of $26.30 and a one year high of $32.42.

A number of equities research analysts recently commented on RHHBY shares. Zacks Investment Research upgraded shares of Roche Holdings AG Basel from a “hold” rating to a “strong-buy” rating and set a $35.00 price target for the company in a report on Wednesday, September 12th. ValuEngine upgraded shares of Roche Holdings AG Basel from a “sell” rating to a “hold” rating in a report on Monday, July 30th. Bank of America lowered shares of Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a report on Monday, September 10th. Finally, Cowen reiterated a “buy” rating and set a $34.00 price target on shares of Roche Holdings AG Basel in a report on Thursday, July 26th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $34.50.

Roche Holdings AG Basel Company Profile

Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

Featured Story: Dividend Aristocrat Index

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Childrens Place  Rating Lowered to Sell at ValuEngine
Childrens Place Rating Lowered to Sell at ValuEngine
-$1.73 EPS Expected for Clovis Oncology  This Quarter
-$1.73 EPS Expected for Clovis Oncology This Quarter
GSA Capital Partners LLP Sells 26,600 Shares of Zix Co.
GSA Capital Partners LLP Sells 26,600 Shares of Zix Co.
GSA Capital Partners LLP Grows Holdings in Magnachip Semiconductor Corp
GSA Capital Partners LLP Grows Holdings in Magnachip Semiconductor Corp
Analyzing Webco Industries  and Synalloy
Analyzing Webco Industries and Synalloy
Apollo Currency Price Reaches $0.0004 on Top Exchanges
Apollo Currency Price Reaches $0.0004 on Top Exchanges


© 2006-2018 Ticker Report